MedTrace Logo

A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease

NCT00920946 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 403

Last updated 2016-10-12

No results posted yet for this study

Summary

The purpose of this study is to determine if Dimebon is safe and effective for the treatment of cognitive impairment in Huntington disease.

Conditions

  • Huntington Disease

Interventions

DRUG

Dimebon

20 mg Dimebon orally TID

OTHER

Placebo

Orally TID

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Medivation, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2011-07-31

Countries

  • United States
  • Australia
  • Canada
  • Denmark
  • Germany
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00920946 on ClinicalTrials.gov